PhRMA 2014: IP, Research, and Reputation
This article was originally published in RPM Report
Executive Summary
NIH research support, intellectual property protections, and restoring the drug industry’s image moved up on the list of podium priorities at the PhRMA annual meeting in Washington, DC.
You may also be interested in...
Washington Threatens; Wall Street Reacts
The biotech investment boom hit the brakes at the end of the first quarter when Rep. Henry Waxman (D-Calif.) publicly complained about Gilead’s pricing for the hepatitis C therapy Sovaldi. The fact that Waxman’s attack has little substantive impact didn’t seem to matter. Another Washington threat—to undo “tax inversion” strategies—is probably much more real, but may actually boost the sector for the rest of 2014.
Defense-to-Offense: PhRMA Readies to Protect Government Markets
White House budget targeting biopharma with new cuts hits just as the Pharmaceutical Research & Manufacturers of America’s annual meeting gets under way.
How Should Pharma Feel About Reform? It Depends Who You Ask
The PhRMA annual meeting took place just days before the make or break vote on health care reform. Here is a sampling of what speakers at that event said about how industry should feel about the legislation.